The present study revealed that treatment with an anti-ACE2 antibody effectively countered the effects of S1 protein on the expression of pro-COL1A1 and TGF-β1 in CFs. Here, COL1A1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.